![Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of all Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets that are Within Expiry | FDA Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of all Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets that are Within Expiry | FDA](https://www.fda.gov/files/styles/recall_image_small/public/4_0.jpg?itok=Xx-VCElE)
Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of all Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets that are Within Expiry | FDA
![Teva selects North Jersey site for its new North American headquarters. - Philadelphia Business Journal Teva selects North Jersey site for its new North American headquarters. - Philadelphia Business Journal](https://media.bizj.us/view/img/10278469/unknown-6*1200xx2016-1136-0-122.jpg)
Teva selects North Jersey site for its new North American headquarters. - Philadelphia Business Journal
![Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges | CNN Business Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges | CNN Business](https://media.cnn.com/api/v1/images/stellar/prod/230821162715-teva-pharmaceuticals-file-restricted.jpg?c=16x9&q=h_720,w_1280,c_fill)
Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges | CNN Business
![Attorney Carter G. Phillips, representing generic drug maker Mylan Pharmaceuticals, departs the Supreme Court in Washington, Wednesday, Oct. 15, 2014, after arguments in Teva Pharmaceuticals U.S.A., Inc. v. Sandoz, Inc. Justices seem Attorney Carter G. Phillips, representing generic drug maker Mylan Pharmaceuticals, departs the Supreme Court in Washington, Wednesday, Oct. 15, 2014, after arguments in Teva Pharmaceuticals U.S.A., Inc. v. Sandoz, Inc. Justices seem](https://c8.alamy.com/comp/2N3T00B/attorney-carter-g-phillips-representing-generic-drug-maker-mylan-pharmaceuticals-departs-the-supreme-court-in-washington-wednesday-oct-15-2014-after-arguments-in-teva-pharmaceuticals-usa-inc-v-sandoz-inc-justices-seem-divided-as-it-considers-a-high-stakes-patent-dispute-between-rival-pharmaceutical-companies-over-the-worlds-best-selling-multiple-sclerosis-treatment-a-case-that-threatens-to-cut-into-the-4-billion-a-year-profits-that-israel-based-teva-pharmaceutical-industries-ltd-earns-selling-the-drug-copaxone-teva-claims-the-us-court-of-appeals-for-the-federal-circuit-w-2N3T00B.jpg)